6 assets in Nasopharyngeal Squamous Cell Carcinoma

Therapeutic assets addressing Nasopharyngeal Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Irinotecan Nasopharyngeal Squamous Cell Carcinoma	AIDS Malignancy Consortium	P1/2	B (60)
Carboplatin Nasopharyngeal Squamous Cell Carcinoma	Rapa Therapeutics LLC	P1/2	B (57)
Autologous Rapamycin-Resistant Th1/Tc1 Cells Rapa-201 Nasopharyngeal Squamous Cell Carcinoma	Rapa Therapeutics LLC	P1/2	CCC (48)
Pembrolizumab Nasopharyngeal Squamous Cell Carcinoma	Rapa Therapeutics LLC	P1/2	CCC (48)
Azacitidine Nasopharyngeal Squamous Cell Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Vorinostat Nasopharyngeal Squamous Cell Carcinoma	AIDS Malignancy Consortium	P1	CC (43)